The importance of BCMA-targeting ADCs and bispecific antibodies in R/R multiple myeloma Published -- Download video MP4 360p Recommendations 01:38 Using BCMA-targeting agents in earlier lines of treatment for multiple myeloma 04:48 The evolution of alloSCT in Richter's transformation and its combination with biological agents 02:01 The evolution of BCL2 inhibition in CLL 02:50 Insights into the CA057-003 trial: mezigdomide, tazemetostat & dexamethasone for R/R myeloma 02:14 The challenges of treating older patients with Hodgkin lymphoma 03:13 3 things to remember when diagnosing patients with MGUS 05:50 Immunotherapy and breast cancer: how does it work? 44:29 What Causes Constipation? - Shocking Facts Behind Constipation | Dr.Ali, Gastroenterologist 08:32 Peter Dauvergne (University of British Columbia, Vancouver, Canada) 09:14 This 1 Thing Can Replace Our Entire Medical System 02:06 Multiple Myeloma - A Rare Cancer | Multiple myeloma is no longer a dead end 35:08 Essential Thrombocythemia with Dr. Raajit Rampal 02:11 Pirtobrutinib as a bridge to CAR-T therapy in B-cell malignancies 02:09 Against Breast Cancer | Patient Response | University Of Westminster 04:45 Orthopaedics in Oxford 02:22 The need for novel agents to treat patients with MCL who have relapsed after targeted therapy 02:49 What are the side effects of immunotherapy? 03:35 Precision medicine and Oxford, challenges and opportunities - Sir John Bell GBE Similar videos 23:13 Bispecific Antibodies in Multiple Myeloma | Dana-Farber Cancer Institute 01:15 How BCMA targeting bispecific antibodies may impact the subsequent use of CAR-T therapy in myeloma 00:41 FcRH5 & GPRC5D bispecific antibodies: antigen targets beyond BCMA for multiple myeloma 55:48 Hitting the BCMA Target in Multiple Myeloma 04:37 Future of BCMA-Targeted Therapies in Multiple Myeloma 07:06 Efficacy and safety of elranatamab BCMA-CD3 bispecific antibody, in patients with RRMM 02:24 BCMA-Targeted Therapies in Multiple Myeloma 08:13 BCMA-targeted BiTEs for multiple myeloma 19:00 Symposium | Beyond BCMA: Novel strategies using bispecific antibodies 06:35 The benefits of bispecific antibodies for treating multiple myeloma 04:21 BCMA-targeting therapies in myeloma 04:15 What’s Next for BCMA-Targeted ADCs and CAR-T Therapy in RRMM? 19:37 Bispecific Monoclonal Antibodies and CAR T-Cell Therapy in Multiple Myeloma, Omar Nadeem, MD 02:00 Treating multiple myeloma resistant to BCMA-targeted therapy 02:19 Sequencing BCMA-targeted agents in multiple myeloma 03:34 Exciting results for BCMA/CD3 bispecific elranatamab (PF-3135) in R/R MM 17:05 BCMA in Multiple Myeloma: Emerging Targeted Solutions 05:59 Bispecific Antibodies for Multiple Myeloma 08:31 How to decide between bispecific antibodies or CAR T-cell therapies More results